skip to main content
Idioma:

Trends in asthma-related direct medical costs from 2002 to 2007 in British Columbia, Canada: a population based-cohort study

Bedouch, Pierrick ; Sadatsafavi, Mohsen ; Marra, Carlo A ; FitzGerald, J Mark ; Lynd, Larry D Caylà, Joan A.

PloS one, 2012-12, Vol.7 (12), p.e50949-e50949 [Periódico revisado por pares]

United States: Public Library of Science

Texto completo disponível

Citações Citado por
  • Título:
    Trends in asthma-related direct medical costs from 2002 to 2007 in British Columbia, Canada: a population based-cohort study
  • Autor: Bedouch, Pierrick ; Sadatsafavi, Mohsen ; Marra, Carlo A ; FitzGerald, J Mark ; Lynd, Larry D
  • Caylà, Joan A.
  • Assuntos: Adolescent ; Adult ; Aged ; Analysis ; Anti-Asthmatic Agents - economics ; Anti-Asthmatic Agents - therapeutic use ; Asthma ; Asthma - drug therapy ; Asthma - economics ; British Columbia ; Child ; Child, Preschool ; Cohort analysis ; Cohort Studies ; Collaboration ; Corticoids ; Corticosteroids ; Cost analysis ; Costs ; Costs and Cost Analysis ; Drugs ; Economic aspects ; Epidemiology ; Female ; Health Care Costs - trends ; Health care expenditures ; Health care policy ; Health insurance ; Hospitals ; Humans ; Lung diseases ; Male ; Medical economics ; Medical research ; Medicine ; Medicine, Experimental ; Middle Aged ; Occupational health ; Patient satisfaction ; Patients ; Pharmaceutical sciences ; Population ; Population studies ; Population-based studies ; Prevalence ; Social and Behavioral Sciences ; Statistical models ; Thorax ; Trends ; Young Adult
  • É parte de: PloS one, 2012-12, Vol.7 (12), p.e50949-e50949
  • Notas: ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
    Conceived and designed the experiments: PB MS JMF CM LL. Performed the experiments: PB MS. Analyzed the data: MS. Contributed reagents/materials/analysis tools: LL CM. Wrote the paper: PB MS.
    Competing Interests: The content of this article is the sole responsibility of the authors. Dr. FitzGerald has served on advisory boards for GlaxoSmithKline, AstraZeneca, Novartis, Pfizer, Boehringer-Ingelheim, Altana, Merck and Topigen. He has also been a member of speakers’ bureaus for Glaxo-SmithKline, AstraZeneca, Boehringer-Ingelheim, Pfizer and Merck. He has received research funding paid directly to the University of British Columbia from the Canadian Institutes of Health Research, AstraZeneca, Glaxo-SmithKline, Boehringer-Ingelheim, Merck, Wyeth, Schering, Genentech and Topigen. Dr. FitzGerald is a member of the Global Initiative for Asthma (GINA) and is chair of the GINA Science Committee. Dr. Bedouch has received financial support for research activities from drug companies including Actelion, Bioprojet, Glaxo-SmithKline. He has had access to unrestricted grants from Sanofi-Aventis France and the Grenoble University Hospital, France. He has also received fees from Actelion for participation in scientific advisory board. Dr. Sadatsafavi was funded by a Canadian Institutes of Health Research fellowship award. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
  • Descrição: Asthma-related health resource use and costs may be influenced by increasing asthma prevalence, changes to asthma management guidelines, and new medications over the last decade. The objective of this work was to analyze direct asthma-related medical costs, and trends in total and per-patient costs of hospitalizations, physician visits, and medications. A cohort of asthma patients from British Columbia (BC), Canada, was created. Asthma patients were identified using a validated case definition. Costs for hospitalizations, physician visits, and medications were calculated from billing records (in 2008 Canadian dollars). Trends in total and per-patient costs over the study period were analyzed using Generalized Linear Models. 398,235 patients satisfied the asthma case definition (mid-point prevalence 8.0%). Patients consumed $315.9 million (M) in direct asthma-related health resources between 2002 and 2007. Hospitalizations, physician visits, and medication costs accounted for 16.0%, 15.7% and 68.2% of total costs, respectively. Cost of asthma increased from $49.4 M in 2002 to $54.7 M in 2007. Total annual costs attributable to hospitalizations and physician visits decreased (-39.8% and -25.5%, respectively; p<0.001), while medication costs increased (+38.7%; p<0.001). This population-based analysis shows that the total direct cost of asthma in BC has increased since 2002, mainly due to a rise in asthma prevalence and cost of medication. Combination therapy with inhaled corticosteroids/long-acting beta-agonists has become a significant component of the cost of asthma. Although billing records capture only a fraction of the true burden of asthma, the simultaneous increase in medication costs and reductions in hospitalization and physician visit costs provides valuable insight for policy makers into the shifts in asthma-related resource use.
  • Editor: United States: Public Library of Science
  • Idioma: Inglês
Links
Voltar para lista de resultados
Ir para página anteriorAnterior Resultado  5 AvançarIr para próxima página

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.